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Type I collagen is a heterotrimeric extracellular matrix pro-
tein consisting of two 1(I) chains and one 2(I) chain. During
liver fibrosis, activated hepatic stellate cells (HSCs) are the
major source of the type I collagen that accumulates in the dam-
aged tissue. Expression of 1(I) and 2(I) collagen mRNA is
increased 60-fold compared with quiescent stellate cells and is
due predominantly to post-transcriptional message regulation.
Specifically, a stem-loop structure in the 5-untranslated region
of1(I) collagenmRNAmay regulatemRNA expression in acti-
vatedHSCs through its interaction with stem-loop binding pro-
teins. The stem-loopmay also be necessary for efficient produc-
tion and folding of the type I collagen heterotrimer. To assess
the role of the stem-loop in type I collagen expression in vivo, we
generated a knock-in mouse harboring a mutation that abol-
ished the stem-loop structure. Heterozygous and homozygous
knock-in mice exhibited a normal phenotype. However, steady-
state levels of 1(I) collagen mRNA decreased significantly in
homozygous mutant MEFs as well as HSCs; intracellular and
secreted type I collagen protein levels also decreased. Homozy-
gous mutant mice developed less liver fibrosis. These results
confirm an important role of the 5 stem-loop in regulating type
I collagen mRNA and protein expression and provide a mouse
model for further study of collagen-associated diseases.
The collagen family is a group of extracellular matrix pro-
teins involved in a variety of biological processes, including pro-
viding structural support to connective tissue and forming the
basement membrane of organs (1, 2). Type I collagen is a het-
erotrimeric protein comprised of two 1(I) collagen chains and
one 2(I) collagen chain, and although located on different
chromosomes, these genes are coordinately regulated in a
developmental, tissue-specific, and inducible manner (3, 4).
The three peptide chains form a triple-helical structure, with
several post-translational modifications resulting in multiple
inter- and intrachain interactions, providing the protein with
increased stability (5, 6). Increased expression anddeposition of
type I collagen are the most dramatic aspects of liver fibrosis,
although expression of other collagens, including type III, is
also increased (4). Activated hepatic stellate cells (HSCs)2 are
the major source of type I collagen in the fibrotic liver (7).
Expression of type I collagen is very low in quiescent HSCs,
which act as a storage site of vitamin A and regulate blood flow
through the hepatic sinusoid. However, following a fibrogenic
stimulus,HSCs undergo an activation process, characterized by
a loss of the vitamin A stores; increased cellular proliferation,
migration, and contractility; and increased synthesis of both
1(I) and 2(I) collagen mRNA and type I collagen protein (8).
Type I collagen biosynthesis is a complex process that is reg-
ulated at both the transcriptional and post-transcriptional lev-
els. Many of these regulatory processes differ in the quiescent
versus activated HSC phenotype. Activated HSCs show a
50–60-fold increase in1(I) collagenmRNAexpression, with a
3-fold increase in gene transcription and a 16-fold increase in
mRNA stability (9). Like many mRNAs (10) (11), the 1(I) col-
lagen gene contains regulatory elements located within both
the 3- and 5-UTRs, which are involved in message stability
and processing (12). In particular, an evolutionarily conserved
sequence located 75 nucleotides downstream of the 5 7-
methylguanine cap (involved in translation initiation (13))
encompasses the translational start codon and is able to form a
stem-loop (5 SL) structure (this stem-loop is also found in
2(I) and 1(III) mRNA (14)). Reporter gene assays revealed
that the 5 SL inhibited1(I) collagenmRNAsteady-state levels
in quiescent HSCs and that mutation of the sequence resulted
in increased mRNA levels; this inhibition was reduced in acti-
vated HSCs through interactions of the SL with RNA-binding
proteins, indicating the SL is important in regulating 1(I) col-
lagen mRNA expression during fibrogenesis (15–17).
The type I collagen protein is also regulated at the transla-
tional and post-translational levels. Modifications such as
cleavage of pro-domains, hydroxylation of proline and lysine
residues in the GXY repeats of the triple-helical region (where
G is glycine, and X and Y are often proline and hydroxyproline,
respectively (18)), and the formation of disulfide bonds are nec-
essary to ensure proper folding of the constituent chains and to
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provide intra- and interchain stabilization interactions (6).
Transfection studies indicated that although the 5 SL appeared
to be inhibitory to translation in vitro, binding of proteins to the
SL in vivo resulted in proper translation (19). However, mutat-
ing the 5 SL resulted in a type I collagen species that was sus-
ceptible to protease degradation; as such, it has been suggested
that the 5 SL is also important in regulating translational effi-
ciency of the 1(I) collagen gene (19).
Analysis of the 5 SL of 1(I) collagen has for the most part
been performed in cell culture studies using exogenous
mutated mRNAs or molecular decoys. Therefore, we looked to
extend the understanding of this element to a more physiolog-
ically relevant in vivo system. In this study we have generated a
knock-in mouse harboring a sequence mutation in the 5-UTR
stem-loop that prevents formation of its secondary structure.
Characterization of embryonic fibroblasts demonstrated that
mutation of the SL resulted in decreased steady-state levels of
1(I) collagen mRNA expression and, in turn, type I collagen
protein in mouse embryonic fibroblasts (MEFs) and in acti-
vated HSCs. Furthermore, mice homozygous for the SL muta-
tion had decreased liver fibrosis and collagen accumulation in
response to liver injury. Thus, the 5 SL is critical in regulating
expression of 1(I) collagen mRNA in MEFs and HSCs.
EXPERIMENTAL PROCEDURES
Generation of Targeting Construct—Briefly, a 2.8-kbHindIII/
HpaI restriction fragment of mouse genomic DNA clone p1a
containing 2.3 kb of upstream promoter sequence, the first
exon, and 300 bp of the first intron of 1(I) collagen was cloned
intoHindIII/HpaI sites in the pGL3 vector (Promega,Madison,
WI) (supplemental Fig. S1A). Amutation in the 5 SLwas intro-
duced by cloning a double-stranded oligonucleotide into the
BstXI and XbaI sites of the pGL3 construct. This mutation
changed 21 nucleotides of the 5 end of the stem-loop, intro-
duced an EcoRI restriction site, and eliminated binding of
LARP6 (17). From this clone, a NheI/StuI fragment was sub-
cloned into the OSDupDel vector (a gift of Dr. Oliver Smithies,
University ofNorthCarolina) atNheI/ClaI (blunt) sites 5of the
neomycin cassette. The second fragment, a 7.7-kb genomic StuI
fragment of p1a containing the remaining 1.2 kb of the first
intron and an additional 6.5 kb of downstream exons and
introns, was cloned into SalI/NotI of the above OSDupDel vec-
tor 3 of the neomycin cassette. The plasmid also contained an
ampicillin resistance cassette for positive selection of clones
and a herpesvirus thymidine kinase cassette for negative
selection.
Generation and Selection of 5 SL Mutant Mouse—TC1 ES
cells (provided by Dr. Beverly Koller, University of North Car-
olina) derived from the 129 mouse strain were maintained on
irradiated MEFs in ES medium (DMEM-high glucose contain-
ing 15% ES-qualified FBS (Invitrogen, Carlsbad, CA), 0.1 mM
-mercaptoethanol, and 2 mM L-glutamine). PmeI-linearized
OSDupDel-SLMut plasmid was introduced to the ES cells by
electroporation. The cells were suspended in 0.3ml of PBSwith
13 g of plasmid DNA and pulsed in a 2-mm gap electropora-
tion cuvette with 270 V, 50 microfarads, and 350  for 0.4 s
using an Electro Cell Manipulator 630 (BTX, Holliston, MA).
The cells were immediately plated on neomycin-resistant, sub-
lethally irradiatedMEFs in ESmedium. After 24 h, themedium
was replaced, and the cells were grown in ES medium contain-
ing 200 g/ml G418 (Invitrogen, Carlsbad, CA); after an addi-
tional 24 h, 1 g/ml ganciclovir was added to the medium.
Individual G418/ganciclovir-resistant ES colonies were
expanded and screened for proper recombination by Southern
blotting. Genomic DNA was isolated by standard techniques
(20), digested with EcoRI, separated on a 0.8% agarose Tris ace-
tate-EDTA gel, and transferred to a nylon membrane (Milli-
pore, Bedford, MA), followed by UV-cross-linking of the
blot. The blot was hybridizedwith two probes to ensure homol-
ogous recombination (supplemental Fig. S3). The first probe
(Recomb) binds a region of endogenous genomic DNA located
outside the construct DNA and was generated by RT-PCR of
mouse NIH3T3 RNA using Moloney murine leukemia virus-
reverse transcriptase (Invitrogen, Carlsbad, CA) and TaqDNA
polymerase (Invitrogen, Carlsbad, CA). The primer sequences
are: sense, 5-TGCCCACCCCCACATACAGC-3, and anti-
sense, 5-CACGCCACGCCACGCCACCTCATCTT-3. The
second probe (Neo) binds within the neomycin resistance
cassette of the construct andwas generatedbyPCRofOSDupDel-
SLMut plasmid DNA. The primer sequences are: sense,
5-TGACGCGTGTGGCCTCGAACAC-3, and antisense,
5-TGAGCCTGGC GAACAGTTCGGC-3.
The probeswere labeledwith [-32P]dCTPusing the random
primedDNA labeling kit (Roche Applied Science, Indianapolis,
IN); each hybridization was performed by incubating 12.5 
1012 counts of probe with the membrane for 1 h at 68 °C in
Rapid-Hyb buffer (GEBiosciences, Buckinghamshire, UK). The
blot was washed once with 2 SSC, 0.1% SDS; washed once
with 0.2 SSC, 0.1% SDS (each for 20 min at 55 °C); and ana-
lyzed the following day using a Typhoon 8600 PhosphorImager
(GE Biosciences, Buckinghamshire, U.K.). Two positive het-
erozygous clones were weaned off feeder cells and expanded on
0.1% gelatin-coated culture plates in ES medium containing
1000 units/ml recombinant leukemia inhibitory factor (Chemi-
con, Temecula, CA) tomaintain the cells in an undifferentiated
state. Expanded clones were karyotyped to ensure the absence
of chromosomal abnormalities.
Generation and Genotyping of Mouse Line—One positive
undifferentiated ES clone was expanded, microinjected into
blastocysts, and implanted in C57BL/6 surrogate females (Ani-
mal Models Core, University of North Carolina). Successful
introduction of the ES cell DNAwas determined by the appear-
ance of chimeric offspring. Males of 70–80% chimerism were
bred with wild-type C57BL/6 females. Successful integration of
the mutation into the germ line was determined by the appear-
ance of agouti (F1) offspring; genotyping by Southern blot
(as described above) confirmed the mutation. F1 heterozygote
males and females were intercrossed, and the resulting off-
spring were bred to perform MEF isolations and initial pheno-
typing. As before, genotyping was performed by Southern blot.
All of the animal work was approved by the University’s Insti-
tutional Animal Care and Use Committee.
Mouse HSC Isolation—HSCs were isolated through collage-
nase-Pronase perfusion of livers, followed by 8.2% Nycodenz
(Accurate Chemical and Scientific Corporation, Westbury,
NY) two-layer discontinuous density gradient centrifugation
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resulting in 99% purity of HSCs as confirmed by retinoid auto-
fluorescence (21). After the isolation, HSCs were plated and
cultured on plastic dishes with 10% FBS supplemented DMEM
for 7 days, and then the cells were analyzed.
Model of Hepatic Fibrosis—Specific pathogen-free WT
(Balb/c/J) and 5 SLmutantmice backcrossedwithBalb/c back-
ground eight times were used for this study. For the bile duct
ligation (BDL) model, 8–12-week-old mice were anesthetized.
After laparotomy, the common bile duct was ligated twice, and
the abdomen was closed. The sham operation was performed
similarly without BDL. Themice received humane care accord-
ing to National Institutes of Health recommendations outlined
in the Guide for the Care and Use of Laboratory Animals. All of
the animal experiments were approved by the Columbia Uni-
versity and University of California, San Diego Institutional
Animal Care and Use Committee.
Measurement of Hepatic Collagen Content—Hepatic hydro-
xyproline content was measured as described previously (21).
Hepatic collagen content was also quantitated by Sirius red
staining of paraffin-embedded sections. The Sirius red-positive
area was analyzed in six random fields (100) on each slide
and quantified using National Institutes of Health imaging
software.
Ribonuclease Protection Assays—MEFs were isolated by
standard techniques (20). Total RNA was isolated from MEFs
using TRIzol reagent (Invitrogen, Carlsbad, CA), and ribo-
nuclease protection assays (RPAs) were performed as
described previously (22). Antisense probes for mouse 1(I)
collagen were designed by RT-PCR of NIH3T3 RNA (wild-
type probe) or PCR from the OSDupDel-SLMut plasmid
(mutant probe). The primer sequences are: wild type: sense,
5-CCGCAAAGAGTCTACATGTC-3, and antisense, 5-
ACACAGCCGTGCCATTGTGG-3; mutant: sense, 5-CTC-
GGGACGGAGCAGGAG-3, and antisense, 5-GAATTCTG-
TGTACGAGCAATTCTA-3. Antisense probe for mouse
2(I) collagen was designed by RT-PCR of NIH3T3 RNA. The
primer sequences are: sense, 5-GGTTTCCAAGGACCTGCT-
3, and antisense, 5-CTTTGAAGCCAGGAAGTCC-3. The
productswere cloned into BlueScript SK (Stratagene, La Jolla,
CA) under the control of the T7 promoter; an antisense probe
against mouse glyceraldehyde-3-phosphate dehydrogenase
(p-TRI-GAPDH; Ambion, Austin, TX) was used as a loading
control. [-32P]UTP-labeled probes were incubated with 5 g
of RNA, and the protected fragments were subjected to electro-
phoresis in 5% acrylamide urea sequencing gels; the gels were
subsequently fixed in 10%methanol:10% acetic acid for 15min,
followed by autoradiography and quantitation on a Typhoon
8600PhosphorImager, using 5g ofNIH3T3RNAas a normal-
ization control.
Protein Extraction andWestern Blotting—Whole cell protein
lysate was extracted fromMEFs and HSCs by a 20-min incuba-
tion at 4 °C in Dignam C buffer (10 mM HEPES, pH 7.9, 0.42 M
NaCl, 1.5 mM MgCl2, 0.5 mM dithiothreitol, 25% glycerol, and
0.5% Nonidet P-40) containing 10 mM 4-nitrophenyl phos-
phate, 20 mM -glycerophosphate, 500 M Pefabloc, 2 g/ml
aprotinin, 50M sodium orthovanadate, and 0.5g/ml leupep-
tin. The samples were centrifuged for 10 min at 14,000  g at
4 °C. The supernatant was collected, and the protein concen-
trationwas determined using theBradford assay (Bio-Rad,Her-
cules, CA). Protein lysate was separated by 7.5% SDS-PAGE
under native or denaturing conditions and transferred to nitro-
cellulose membrane (Schleicher & Schuell, Keene, NH). Equal
protein loading was determined by Ponceau S staining (Sigma-
Aldrich, St. Louis,MO) of the transfer blot and byWestern blot
using 1:1000 goat anti-actin (Santa Cruz Biotechnology, Santa
Cruz, CA) or 1:1000 mouse anti--tubulin (Zymed Labs, San
Francisco, CA) primary antibodies and 1:1000 rabbit anti-goat
or goat anti-mouse HRP-conjugated secondary antibodies
(Santa Cruz Biotechnology, Santa Cruz, CA). Blotting was
performed as described (23), using 1:1000 rabbit anti-colla-
gen type I (Rockland, Gilbertsville, PA), and 1:1000 goat anti-
rabbit HRP-conjugated secondary antibody (Santa Cruz Bio-
technology, Santa Cruz, CA). Protein expression was detected by
enhancedchemiluminescence (AmershamBiosciences,Arlington
Heights, IL), and expression levels were quantified by densitome-
try using AlphaEase software (Alpha-Innotech Corporation, San
Leandro, CA).
Collagen Secretion Western Blotting—MEFs or HSCs were
washed twice with PBS, fresh DMEM-high glucose medium
containing 10% FBS was added to the cells, and aliquots were
removed at the indicated time points. The aliquots were sepa-
rated by 7.5% SDS-PAGE; blotting was performed with rabbit
anti-type I collagen as described above and with 1:1000 mouse
anti-fibronectin (BD Transduction Laboratories, Lexington,
KY) with 1:1000 goat anti-mouse HRP-conjugated secondary
antibody.
Cre-mediated Removal of Neomycin Cassette—Wild-type
and mutant MEFs were plated on 60-mm cell culture dishes at
a density of 20 104 cells/dish. The cells were transduced over-
night with either AdCre or Ad-Track CMV (which expresses
GFP under the cytomegalovirus promoter) adenovirus in
DMEM containing 2% FBS at a multiplicity of infection of
6000, which resulted in90% transduction efficiency (data not
shown). The following day, the viral medium was removed and
replaced with DMEM containing 10% FBS; 36 h post-transduc-
tion, themediumwas collected, and the cells were harvested for
RNA (as described under “Ribonuclease Protection Assays”).
Genomic DNA was isolated from additional dishes using the
Puregene Cell & Tissue DNA Purification System (Gentra,
Minneapolis, MN).
Polymerase Chain Reaction Assays—To determine splicing
efficiency of the mutant transcript, human 293A cells were
transfected with 5 g of OSDupDel-SLMut plasmid or empty
vector using Lipofectamine reagent (Invitrogen, Carlsbad, CA);
48 h post-transfection, cellular RNA was harvested using
TRIzol, and RNA samples were reverse-transcribed, followed
by PCR amplification. PCRprimerswere designed such that the
sense primer bound to a region within the first exon of the
mouse1(I) collagen gene,whereas the antisense primer bound
to a region within the second exon (supplemental Fig. S2A).
The primer sequences were: sense, 5-CTCGGGACGGAGC-
AGGAG-3, and antisense, 5-ACACAGCCGTGCCATTG-
TGG-3. For confirmation of neomycin cassette removal using
AdCre, 100 ng of MEF genomic DNA was amplified using
primers that flanked the cassette. The primer sequences were:
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sense, 5-GCAGGGTTCCTCCCAGCTCT-3, and antisense,
5-AGCCGGGTCCTTCAAAGCCAG-3.
mRNA Stability Assay—Wild-type or SL mutant MEFs were
treatedwith actinomycinD (5 ng/ml) orDMSO inDMEMcon-
taining 10% FBS. The cells were lysed at 0, 4, 8, 12, 18, and 24 h
after treatment. RNA was isolated by RNeasy kit (Qiagen)
and reverse-transcribed using random hexamer primer. Real
time quantitative PCR was performed with an ABI 7000
sequence detection system (Applied Biosystems, Foster
City, CA) using an 1(I) collagen primer-probe set
(Mm00801666_g1; ABI, Foster City, CA) for 40 cycles of 15 s
at 95 °C and 60 s at 60 °C. Quantification was performed
by comparing the Ct values of each sample to a standard
curve and normalization to 18 S (primer probe set
(Hs99999901_s1; ABI, Foster City, CA).
Statistical Analysis—Student’s t test was used to determine
statistical significance between groups. A p value  0.05 was
considered significant.
RESULTS
1(I) Collagen 5-UTR SL Construct—Approximately 10.5
kb of mouse genomic DNA containing the 1(I) collagen
sequence, harboring a mutation in the 5-UTR stem-loop
sequence that abolished SL formation, was cloned into the
OSDupDel targeting vector (supplemental Fig. S1A). Along
with the 21-nucleotide mutation, an EcoRI restriction site was
included, which was used for genotyping purposes (Fig. 1) but
did not disrupt the translational start codon located within the
loop. The short arm of the construct contained 2.8 kb of
genomic DNA, incorporating 2.3 kb of upstream sequence, the
first exon (including the SL mutation), and a 300-bp portion of
the first intron. The long arm included the remaining 1.2 kb of
the first intron and 6.5 kb of additional downstream sequence.
A neomycin cassette was located between the arms and within
the first intron,making the entire insert12.8 kb in length. The
product of a successful homologous recombination event
would result in introduction of the SL mutation along with the
neomycin cassette into the genome (supplemental Fig. S1B).
The 5-UTR SL Mutation Did Not Affect Splicing Efficiency—
RT-PCR was performed on 293 cells transfected with SL
mutant plasmid to determine whether insertion of the mutant
construct affected the capability to splice1(I) collagenmRNA.
A PCR primer set was generated such that the sense primer
bound within the first exon of the message, whereas the anti-
sense primer bound within the second exon (supplemental Fig.
S2A). If proper splicing occurred, the expected PCR product
would be 290 bp; however, because of the neomycin cassette
within the first intron, if the message was not efficiently or
properly spliced, a product of 3020 bp would be observed. As
shown in supplemental Fig. S2B, only the smaller PCR product
was detected in cells transfected with the SL mutant plasmid;
cells transfected with the empty vector generated no product.
The efficiency of production of the large PCR product was con-
firmed using the SL mutant plasmid as a template.
Generation of the 5-UTR SLMutation ES Cells—The linear-
ized targeting construct was electroporated into 129 strain
embryonic stem cells, and clones were positively selected for
homologous recombination and negatively selected against
random integration. Individual clones were isolated and
expanded, and homologous recombination was assessed using
two Southern blot probes. Following EcoRI digestion of the ES
DNA, the first probe (Recomb) bound to a region outside the
recombined construct DNA and generated a 4.1-kb fragment if
the SLmutation was properly inserted (supplemental Fig. S3B).
In addition, because the neomycin cassette contained an EcoRI
site, proper homologous recombination was further confirmed
using a second probe (Neo), which bound the cassette down-
stream of the restriction site, generating a 10.3-kb fragment.
Digested wild-type DNA would generate a 13.9-kb band with
theRecomb probe and no bandwith theNeo probe. As shown in
supplemental Fig. S3, several clones were positive for proper
homologous recombination (see lanes 7 and 8). Positive
heterozygous clones had normal chromosomal karyotypes
(data not shown).
Mutation of the 5-UTR SL Decreased Steady-state Levels of
1(I) Collagen mRNA in Mouse Embryonic Fibroblasts—Fol-
lowing successful generation ofmice harboring the 5 SLmuta-
tion, themutantmice had normal development, grossly normal
phenotype, and normal fertility. This was somewhat surprising,
given the role of type I collagen in growth and development (see
“Discussion”). RNA was harvested from MEFs isolated from
wild-type and mutant mice and subjected to RPAs using 1(I)
collagen-specific probes to analyze effects of the SL mutation
on message expression. Two probes were designed, and both
bound either genotype; however, a portion of each probe bound
specifically to either wild-type or mutant sequence (Fig. 2, A
andB). Digestion of theRNA-probe hybridwould thus generate
FIGURE 1. DNA sequence depicting SL mutation. The entire 5-UTRs for both the wild-type (A) and mutant (B) sequences are shown, with the stem-loop
region in bold; the actual SL mutation is in italics. The translation initiation codons and the EcoRI site inserted into the mutant sequence are underlined.
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protected bands of differing size depending on the genotype of
the cell. The wild-type probe protected a 213-bp fragment of
wild-type RNA, whereas the protected fragment of themutant-
containing RNA was 190 bp; likewise, the mutant probe pro-
tected a 91-bp fragment of mutant RNA and a 68-bp fragment
of wild type. As seen in Fig. 2 (C and D), the wild-type probe
protected the proper fragment for each respective genotype;
similar results were obtained using the mutant probe. Quanti-
tation of the bands revealed an 55% reduction in 1(I)
collagen mRNA expression in mutant cells, regardless of the
probe used (Fig. 2, E and F). To further investigate these
findings, we isolated MEFs from heterozygous embryos and
analyzed the relative contribution of the wild-type and
mutant alleles to the total 1(I) collagen mRNA population
(Fig. 2G, wild-type probe RPA; mutant probe RPA not
shown). RPA results using either riboprobe indicated that
expression of the wild-type allele was approximately twice
that of the mutant, in close agreement with our findings
comparing the alleles separately in homozygous MEFs. No
significant difference in expression of 2(I) collagen mRNA
was detected between WT and mutant MEFs (supplemental
Fig. S4, A and B).
FIGURE 2. Mutation of the 5 SL decreased 1(I) collagen mRNA steady-state levels. A and B, RNase protection assay schematic. An antisense wild-type
probe (A) was designed such that the 3 end binds only wild-type sequence. RNase digestion of the probe-wild-type transcript duplex results in a 213-bp
protected fragment; a 190-bp fragment is protected with mutant RNA (A). An antisense mutant probe (B) was designed such that the 5 end binds only mutant
sequence. Digestion of the probe-mutant transcript duplex results in a 91-bp protected fragment; a 68-bp fragment is protected in wild-type RNA (B). A
nonbinding sequence is indicated by a solid bent line. For the wild-type schematic, the translation initiation codon is underlined. C and D, representative RPA
using wild-type probe. RNA from wild-type (/) and mutant (/) MEFs was incubated with wild-type (C) or mutant (D) riboprobe; each lane represents a
separate cell isolation. L, 50-bp DNA ladder (fragment sizes indicated to the left of the gel); WT, undigested mouse 1(I) collagen wild-type riboprobe; M,
undigested mouse 1(I) collagen mutant riboprobe; G, undigested mouse GAPDH riboprobe; t, yeast tRNA; 3T3, NIH3T3 RNA. Arrow G, protected GAPDH; arrow
WT, protected wild type; arrow M, protected mutant. E and F, result of four independent RPAs using wild-type (E) and mutant (F) probes. 1(I) collagen-specific
bands were quantitated and normalized to GAPDH values. The data are expressed as relative amounts of message versus wild-type MEFs (n 	 12). *, p  0.05.
G, analysis of heterozygote MEFs. Left panel, representative RPA using wild-type riboprobe; each lane represents a separate cell isolation. L, 100-bp DNA ladder
(fragment sizes indicated to the left of the gel); other abbreviations are as described previously. Right panel, graph depicting contribution (as percentages) of
each allele to total 1(I) collagen mRNA levels; expression was quantitated using both wild-type and mutant riboprobes. *, p  0.05, wild-type transcript versus
mutant transcript. For all graphs, the error bars represent S.E.
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Mutation of the 5-UTR SL Decreased Intracellular Type I
Collagen Protein—Because the production and accumulation
of the type I collagen heterotrimer is the end product of the
pathway, we next determinedwhat effectmutation of the stem-
loop had on type I collagen protein expression. As shown in Fig.
3A, intracellular type I collagen expression was decreased
65% in homozygous mutant compared with wild-type MEFs.
This decrease is similar to that observed in the steady-state
levels of 1(I) collagen mRNA (Fig. 2), indicating that there
does not appear to be increased translational activity in the
mutant cells to compensate for reduced RNA levels. A similar
decrease in intracellular type I pro-collagen protein was also
observed under nonreducing conditions (Fig. 3B), which allows
for the detection of the high molecular weight, disulfide-
bonded species of collagen.
We next analyzed the effect ofmutating the 5 SL on collagen
secretion. Collagen levels were decreased in medium harvested
from mutant MEFs over a period of 3 h compared with wild-
type cells (Fig. 3C). Although collagen secretion was clearly
observed after 2 h in wild-type cells, expression was detected
only faintly after 3 h in mutant cells and at levels much lower
than wild type at either 2 or 3 h. This decrease correlated with
the decreased intracellular expression of type I collagen in
mutant MEFs observed in Fig. 3 (A and B).
Removal of the Neo Cassette Had No Effect on 1(I) Collagen
Expression—It is well established that introns control a variety
of mRNA activities, including splicing, nuclear export, cellular
localization, and translational efficiency (24). Previous studies
have reported that interfering with the first intron of 1(I) col-
lagen mRNA can have deleterious effects on collagen expres-
sion (25–27). Although these studies dealt with deletions in the
first intron, evidence suggests that increased intron size can
also influence transcript expression (28, 29).
Because the neomycin cassette is located between loxP sites,
mutant MEFs were transduced with a Cre recombinase-ex-
pressing adenovirus to remove the Neo gene. Transduction of
mutant MEFs with AdCre resulted in complete removal of the
cassette, as determined by PCR genotyping of genomic DNA
(Fig. 4A). The transduced cells contained an additional 34-bp
loxP sequence (compared with wild-type DNA) that remained
after recombination (29). RPA analysis showed that removal of
the cassette resulted in a slight and not significant increase
in 1(I) collagen mRNA steady-state levels compared with
mutant MEFs containing the Neo cassette (Fig. 4B). More
importantly, 1(I) collagen mRNA expression in the AdCre-
transduced mutant MEFs was still decreased in a statistically
significant manner compared with wild-type cells. Adenoviral
conditions had no effect on 1(I) collagen expression, because
FIGURE 3. Mutation of the 5 SL decreased type I collagen protein levels.
A and B, reduced intracellular expression of type I collagen in mutant MEFs.
Intracellular protein (30 g) was harvested from wild-type (/) and mutant
(/) MEFs and separated in denaturing (A, left panel) or nonreducing dena-
turing (B) 7.5% acrylamide gels, followed by Western blotting for type I colla-
gen and actin or -tubulin. Representative Western blots are shown; each
lane represents separate cell isolations. A, right panel, result of six indepen-
dent Western blots. Type I collagen bands were quantitated and normalized
to actin values. The data are expressed as relative amounts of protein versus
wild-type MEFs. *, p  0.05; the error bars represent S.E. C, secretion of type I
collagen is reduced in mutant MEFs. Aliquots (50 l) of media harvested 1, 2,
and 3 h after a change of fresh media from wild-type (/) and mutant (/)
MEFs were separated by 7.5% SDS-PAGE gels, and the blot was probed with
anti-type I collagen and anti-fibronectin. Representative Western blots are
shown.
FIGURE 4. Removal of the neomycin cassette had no effect on 1(I) colla-
gen expression. A, confirmation of cassette removal. Mutant (/) MEFs
were transduced with adenovirus expressing GFP (AdTrack) or Cre recombi-
nase (AdCre). Genomic DNA was isolated, and then PCR was performed using
primers flanking the cassette. The presence of the Cre cassette resulted in a
2373-bp product, whereas the absence of the cassette generated a product of
1109 bp. The products were separated in a 1% agarose gel. M, DNA marker
(fragment sizes indicated to the left of the gel); , water template; P, OSDup-
Del targeting construct; /, wild-type MEFs. B, result of three independent
RPAs using wild-type probe. 1(I) collagen-specific bands were quantitated
and normalized to GAPDH values. The graph compares 1(I) collagen mRNA
levels in untreated (/ Un) or AdCre-transduced (/ Cre) wild-type MEFs
to untreated (/ Un), AdTrack-transduced (/ GFP), or AdCre-transduced
(/ Cre) mutant MEFs. The data are expressed as relative amounts of mes-
sage versus wild-type untreated cells. *, p  0.05; NS, not significant; the error
bars represent S.E.
The Role of the 1(I) Collagen mRNA 5 Stem-Loop
8614 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 286 • NUMBER 10 • MARCH 11, 2011
mutant MEFs transduced with AdTrack-GFP and wild-type
cells transduced with AdCre exhibited no changes compared
with controls.
Mutation of the SL Did Not Affect Stability of the 1(I) Colla-
gen Message—To gain an understanding of how the 5 SL pos-
itively regulates expression of 1(I) collagenmRNA, we treated
wild-type and SL mutant MEFs with actinomycin D to deter-
mine the effect of SL on message stability (Fig. 5). Somewhat
unexpectedly, both messages exhibited similar half-lives;
althoughmutation of the SL appeared to decrease message sta-
bility, this affect wasminimal (t1⁄2 of 13 h versus 15 h inwild-type
message).
Mutation of the 5-UTR SL Reduced Protein Expression of
Type I Collagen inHSCs—Fig. 3 demonstrates that intracellular
and secreted type I collagen levels were decreased in MEFs. To
investigate whether type I collagen production is also reduced
in mutant HSCs, HSCs were isolated from wild-type and 5 SL
mutant mice. After 7 days culturing, HSCs are fully activated.
Intracellular type I collagen expression was significantly
decreased to 23% in mutant compared with wild-type HSCs
(Fig. 6A). Next, we analyzed the secretion of collagen inmutant
HSCs. Collagen levels were significantly decreased to 33% in
medium harvested from mutant HSCs for 3 h in comparison
with wild-type cells (Fig. 6, B and C). These results demon-
strated that the 5 SL is crucial for collagen production in both
MEFs and HSCs.
We investigated mRNA levels of collagen 1(I), collagen
2(I), collagen 1(III), -SMA, and tissue inhibitor of metallo-
proteinases (TIMP)-1 in wild-type and mutant HSCs (Fig. 6D).
Not only collagen 1(I) but also collagen 2(I) and -SMA
mRNA levels were significantly reduced in mutant HSCs com-
pared with wild-type HSCs (Fig. 6D). These results suggest that
collagen production regulated by 5 SL is associated with HSC
activation.
MiceMutated in 5 SL ShowedReducedHepatic Fibrosis after
BDL—21days after BDL,wild-typemice had significant hepatic
fibrosis, as demonstrated by Sirius red staining and hy-
droxyproline content. In contrast, 5 SL mutant mice had less
fibrosis, as demonstrated by reduced collagen deposition and
hydroxyproline level (Fig. 7, A–C). Fibrogenic gene expression
was determined at 21 days after BDL, including mRNAs for
collagen 1(I), collagen 2(I), collagen 1(III), -SMA, and
TIMP-1. Wild-type mice showed an increased expression of
these genes, whereas 5 SL mutant mice had suppression in
fibrogenic gene expression but not the expression of cyclophy-
line A (Fig. 7D). These results indicated that 5 SL is crucial for
collagen production in liver fibrosis induced by BDL.
DISCUSSION
Liver fibrosis is characterized by increased synthesis and
deposition of extracellular matrix proteins that disrupt the tis-
sue structure, leading to organ dysfunction. Of the extracellular
matrix proteins overproduced during liver fibrosis, type I col-
lagen predominates. Many recent studies have examined acti-
vated HSCs, the main source of type I collagen in the fibrotic
liver, as potential targets for anti-fibrotic therapies (30).
FIGURE 5. Mutation of the SL did not affect 1(I) collagen mRNA stability.
Wild-type (WT) and mutant (Mut) MEFs were treated with 5 ng/ml actinomy-
cin D (ActD) or DMSO. RNA was harvested 4, 8, 12, 18, and 24 h after treatment
and reverse-transcribed; the resulting cDNA was analyzed by real time PCR
using an 1(I) collagen-specific primer. The samples were normalized to 18 S
expression levels.
FIGURE 6. Mutation of the 5 SL in HSCs suppressed collagen 1(I) mRNA
and protein levels. Primary HSCs were isolated from wild-type and mutant
mice. A, intracellular expression of type I collagen was reduced in mutant
HSCs. Intracellular protein (10 g) was harvested from wild-type (/) and
mutant (/) HSCs 7 days after culturing on plastic dishes. Western blotting
for type I collagen and -tubulin was performed. Representative Western
blots are shown; each lane represents a separate cell isolation. B and C, secre-
tion of type I collagen is reduced in mutant HSCs. Aliquots (50 l) of media
harvested 1, 2, and 3 h after change of fresh media from wild-type (/) and
mutant (/) HSCs were separated by 7.5% SDS-PAGE gels, and the blot was
probed with anti-type I collagen (B). Secreted type I collagen in the media 3 h
after change of fresh media is shown (C). Three independent media collec-
tions. Representative Western blots are shown. D, mRNA levels of collagen
1(I), collagen 2(I), collagen 1(III),  smooth muscle actin (SMA), and
TIMP-1 in wild-type (/) and mutant (/) HSCs were measured by quan-
titative real time PCR. The results are shown as fold change compared with
wild-type HSCs. NS, not significant. The error bars represent S.E.
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One aspect of HSC-mediated production of type I collagen
occurs at the mRNA level of the constituent 1(I) and 2(I)
chains. Transcription of both genes is up-regulated during
fibrogenesis, and their expression is enhanced by a various
post-transcriptional regulatory elements. Of particular note is
the presence of a stem-loop structure located in the 5-UTR of
the two genes (31, 32), as well as in the 5-UTR of the 1(III)
gene (33). This SL encompasses the translation initiation codon
(34) and is evolutionarily conserved from sea urchins (35) to
zebrafish (36) to chicks (14) to frogs and humans (15), thus
implicating a vital role for this structure in collagen gene
expression and providing a possible therapeutic target.
To investigate the role of 5 SL on type I collagen in vivo, we
generated a knock-inmouse line harboring amutation in the SL
region that inhibited proper secondary structure formation.
Althoughmany previous studies of the 5 SLwere performed in
HSCs, the concepts involved in the regulation of 1(I) collagen
mRNA apply to all collagen-expressing cells, including fibro-
blasts and HSCs; therefore, we isolated MEFs to initially char-
acterize effects of the SL mutation. Steady-state levels of 1(I)
collagenmRNA in SLmutantMEFswere50%of that found in
wild-type cells, indicating the SL regulates message expression.
This observation was further strengthened by an approximate
2:1 ratio of wild-type to mutant transcript expression in the
RNAof heterozygoteMEFs.Mutation of the SLhadno effect on
expression of 2(I) collagen mRNA, even though transcription
of both genes is generally coordinately regulated, and the stem-
loop sequence of 2(I) collagen is similar to that of 1(I) colla-
gen. This finding was not unexpected, because the mutation
does not affect the promoter region or any transcription factor-
binding sequence, and the two genes do not share the same
regulatory sequences (37).
FIGURE 7. Reduced liver fibrosis in 5 SL mutated mice after bile duct ligation. Wild-type (/) (n 	 6) and 5 SL mutant (/) (n 	 6) mice underwent BDL.
A and B, fibrillar collagen deposition was evaluated by Sirius red staining (A) and its quantification (B) 21 days after BDL. C, hepatic hydroxyproline content was
measured. D, hepatic mRNA levels of collagen 1(I), collagen 2(I), collagen 1(III), -SMA, TIMP-1, and cyclophyline A were measured in wild-type (/) and
5 SL mutant (/) (n 	 5) mice 21 days after BDL by quantitative real time PCR. These genes were normalized to 18 S and are expressed as fold change
compared with sham operated wild-type mice. The original magnification is 100 (A).
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Our results demonstrate that the SL is necessary for efficient
and specific expression of 1(I) collagen mRNA. A previous
study suggested that the SL inhibits 1(I) collagen mRNA
steady-state levels in quiescent HSCs (15). However, it should
be noted that the prior study utilized transient adenoviral trans-
duction of HSCs with artificial reporter gene constructs,
whereas our study utilized endogenous cells from mice with a
germ line-transmitted mutation, thus better reflecting the in
vivo environment. More importantly activated HSCs, more so
than quiescent HSCs, phenotypically resemble collagen-pro-
ducing fibroblasts and myofibroblasts (38, 39).
Another study found that expression of 1(I) collagen
mRNA and 1(I) pro-collagen protein levels were reduced in
activating HSCs treated with “molecular decoys” that mimic
the 5 SL and compete for SL-binding proteins, titrating out
factors necessary for 1(I) collagen mRNA processing (34).
This pointed to a potential correlation between 1(I) collagen
mRNA abundance and message translation and indicated that
the SL may be involved in a coordinated transcription/transla-
tion process, because the decoys may also compete for binding
of protein factors necessary for translation. Additionally,
although the SL inhibited translation of 1(I) collagen in vitro
(similar to previous findings (40)), mutation of the SL resulted
in inefficient formation of triple-helical type I collagen in
Mov-13 fibroblasts.
We observed similar results in SL mutant MEFs and HSCs.
Expression of intracellular type I collagen (both denatured and
disulfide-bonded) was reduced in the mutant cells, furthering
the correlation between 1(I) collagen mRNA abundance and
protein expression. Additionally, secretion studies showed that
mutantMEFs andHSCs exhibited a diminished and/or delayed
secretion of type I collagen in comparison with wild-type cells.
These data indicate that SL mutant-expressing cells do not
increase their rate of protein secretion to compensate for
reduced protein expression.
Stem-loop structures in the UTRs play a critical role in reg-
ulating mRNA processing (41). A canonical example of this is
the interaction of the human immunodeficiency virus type-1
transactivation-responsive region with the Tat transactivator
protein. Binding of Tat to a SL within the transactivation-re-
sponsive region at the 5 end of the RNA ensures proper tran-
scriptional elongation (42); additionally, the binding and sub-
sequent modification of Tat is necessary for proper splicing of
the viralmRNA (43). Given the importance of 5 SLs in enhanc-
ingmessage stability in other systems (44, 45) and the proposed
model that an uncharacterized 120-kDa SL-binding protein
may interact with proteins in the 3-UTR of 1(I) collagen
mRNA to protect against exonuclease activity (15, 38), we
examined whether mutation of the SL resulted in decreased
mRNA stability. Unexpectedly, the mutant mRNA exhibited
only a minimal decrease in stability versus wild type, indicating
that the SL regulates 1(I) collagen mRNA by another
mechanism.
Recently, we cloned a protein that binds the 5 stem-loop of
collagen mRNAs (17). This protein, LARP6, binds 5 SL of col-
lagen 1(I) and 2(I) mRNAs with similar affinity. Knockdown
of LARP6 resulted in greatly reduced collagen protein synthe-
sis, which was a combination of less efficient translation of col-
lagen mRNAs and inefficient folding of the collagen hetero-
trimer. When overexpressed, LARP6 bound 5 SL with affinity
high enough to block ribosomal scanning, resulting in exclu-
sion of collagen mRNAs from the polysomes (17). Based on
these findings, we postulated that LARP6 has a role in coordi-
nation of translation of collagen1(I) and2(I)mRNAs (16). Its
binding to 5 SL may serve to prevent their random translation,
which is a prerequisite for their subsequent coordinated transla-
tion on the membrane of the ER. Coordinated synthesis of 1(I)
and2(I) polypeptides results in higher efficiency of folding of the
heterotrimer of type I collagen. These results are consistent with a
lower degree of fibrosis in mice lacking the 5 SL.
RNA elements are not greatly involved in regulating tran-
scriptional initiation in eukaryotes, although there is some evi-
dence of this in viruses (46); therefore, we do not expect the SL
mutation to affect transcriptional activation. However, in addi-
tion to regulating message stability, the 5- and 3-UTRs regu-
late other eukaryotic mRNA metabolic processes including
transcriptional elongation, post-transcriptional modifications
(capping of the 5 end and 3 polyadenylation), splicing, nuclear
export, subcellular message localization, and translation (41,
47–50). These functions aremediated by the binding of protein
factors to mRNA in the nucleus, the cytoplasm, or both, result-
ing in the formation of a messenger ribonucleoprotein particle
(41). Disruption of the messenger ribonucleoprotein particle
through deletion of the 5 SL could result in improper nuclear
processing and increased degradation of the 1(I) collagen
mRNA; because the 3-UTR sequence is unaffected, poly-
adenylation can still occur, leaving the stability of the mutant
mRNAvirtually unchanged comparedwithwild type. Although
most localization elements are located in the 3-UTR (48),
5-UTR elements can also regulate message localization, as is
the case with Drosophila gurken mRNA (51). Indeed, one
model suggests that the 5 SL targets new 1(I) collagen
mRNAs to distinct regions of the endoplasmic reticulum to
ensure proper translation (19).
Additionally, the current model of RNA processing suggests
that many cytoplasmic messenger ribonucleoprotein particle
proteins, including several heterogeneous nuclear ribonucleo-
proteins and the exon junction complex, associate with the
mRNA in the nucleus and accompany the molecule into the
cytoplasm (41). Mutation of the 5 SL may interfere with inter-
action of these proteins (or associated co-factors) with the1(I)
collagen mRNA inside the nucleus and lead to increased mes-
sage degradation.
Any number ofmutations in either the1(I) or2(I) collagen
chain can impair type I collagen production in humans, result-
ing in the disease osteogenesis imperfecta (“brittle bone dis-
ease”) (18). Based upon the structural support role of type I
collagen and the phenotypic effects of collagen mutations in
osteogenesis imperfecta model mice (52–54), we were some-
what surprised that SLmutant mice developed normally with a
grossly normal phenotype when compared with wild-type lit-
termates. However, this finding is not unprecedented. Several
studies using transgenic mouse models of osteogenesis imper-
fecta and other collagen-related diseases have reported that
mutant mice can lack any readily apparent abnormal pheno-
types (52, 55–57).
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One potential explanation for a lack of phenotype is that
baseline levels of type I collagen produced in the SL mutant
mice are sufficient for normal development, breeding, and sur-
vival; additional levels of collagen in wild-typemicemay simply
serve to provide additional structural support required during
stress. Indeed, some patients with mild forms of osteogenesis
imperfecta do not exhibit any of the characteristic pheno-
types of the disease, even when 75% of the 1(I) collagen
chains contain mutations (18, 58). Furthermore, it has been
reported that mutations that result in synthesis of longer or
shorter 1(I) or 2(I) chains generate more deleterious
effects than those mutations that affect expression of the
constituent chains (59), such as in the case of SL mutant
mice. The SL mutation is not incorporated into the type I
collagen protein; therefore, the effect of the mutation on any
physical phenotype may be subtle and may not present itself
until the mice are physically challenged, as has been shown
in other collagen-based mouse models (55, 60).
Our findings strengthen the importance of the 5 SL of 1(I)
collagen mRNA in regulating mRNA expression in vivo and its
involvement in regulating type I collagen production. The fact
the SL structure has been conserved throughout evolution
underscores its importance. Our findings also enhance the
therapeutic potential of SL decoys, which can decrease collagen
synthesis from endogenous RNA, potentially attenuating liver
fibrosis (34). Finally, we have developed an in vivomousemodel
for studying the 5 SL and its effects on collagen expression and
production in MEFs and HSCs. Indeed, 5 SL mutant mice
showed a significant reduction of liver fibrosis after BDL, con-
firming our concept that 5 SL is crucial for collagen production
in vivo during liver injury.
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